Sor102 !!link!! Guide
Higher rates of and symptomatic response.
Developed by Sorriso Pharmaceuticals , SOR102 isn't just another drug; it’s a first-in-class designed to tackle inflammation from two angles simultaneously while remaining confined to the gastrointestinal tract. The Science: Dual Targeting in a Tablet sor102
Could you clarify which of these you mean? Higher rates of and symptomatic response
:
Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling" SOR102 isn't just another drug
By working directly in the GI tissue, it may achieve higher local concentrations than systemic drugs without increasing the risk of body-wide infections.
: